证券代码：300841 证券简称：康华生物 公告编号：2025-030 一、股东大会审议通过的权益分派方案情况 1、公司 2024 年年度权益分派方案已获 2025 年 5 月 9 日召开的 2024 年年 度股东大会审议通过，具体内容为：以实施权益分派股权登记日登记的总股本（剔 除回购证券专用账户的股份）为基数，向全体股东每 10 股派发现金红利 10 元 （含税），送红股 0 股（含税），以资本公积金向全体股东每 10 股转增 0 股。 在利润分配预案披露日至实施权益分派股权登记日期间，如出现股权激励行权、 可转债转股、股份回购等情形，公司股本总额发生变动的，则以实施分配方案时 股权登记日的享有利润分配权的股份总额为基数，按照每股现金分红金额不变的 原则对分配总额进行调整。 成都康华生物制品股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整、没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、截至本公告披露日，成都康华生物制品股份有限公司（以下简称"公司" 或"本公司"）总股本为 132,946,899 股，公司回购专用证券账户中股份数量为 3,00 ...

证券代码：300841 证券简称：康华生物 公告编号：2025-029 成都康华生物制品股份有限公司 关于注销回购股份并减少注册资本通知债权人的公告 二、通知债权人内容 针对公司本次注销回购股份并相应减少注册资本事项，根据《中华人民共和 国公司法》《深圳证券交易所上市公司自律监管指引第9号——回购股份》等相 关法律、法规的规定，公司特此通知债权人，债权人自本公告之日起四十五日内， 有权凭有效债权文件及相关凭证要求公司清偿债务或者提供相应担保。债权人未 在规定期限内行使上述权利的，不会因此影响其债权的有效性，相关债务（义务） 将由公司根据原债权文件的约定继续履行。 债权人可采用现场、邮寄或电子邮件的方式申报，具体如下： 1、申报时间： 2025年5月12日起45日内（工作日的9:00-11:30、13:30-16:30） 2、申报地点和申报材料送达地点： 四川省成都市龙泉驿区北京路182号 本公司及董事会全体成员保证信息披露内容的真实、准确、完整、没有 虚假记载、误导性陈述或重大遗漏。 一、公司注销部分回购股份减少注册资本的情况 成都康华生物制品股份有限公司（以下简称"公司"） 于2025年4月17日召开 的第 ...

Investment Rating - The report does not explicitly state an investment rating for the vaccine industry Core Insights - The overall trend in the vaccine industry shows a decline in batch approvals for most vaccine types in Q1 2025, with some exceptions showing recovery or growth in demand [7][29][46] Summary by Category Multi-Component Vaccines - In Q1 2025, multi-component vaccines saw a total of 17 batch approvals, a decrease of 26% compared to the previous year [11][15] - The five-component vaccine maintained its batch approval at 17, while the four-component vaccine had no approvals [15][12] Pneumonia Vaccines - Total batch approvals for pneumonia vaccines in Q1 2025 were 23, down 30% year-on-year [19][21] - The 13-valent pneumonia vaccine had 19 approvals, remaining stable, while the 23-valent vaccine saw a significant drop to 4 approvals, down 71% [24][19] HPV Vaccines - HPV vaccine approvals increased to 57 batches in Q1 2025, a growth of 63% [29][27] - The two-valent HPV vaccine saw a remarkable increase of 367%, with all approvals coming from Wantai Biological Pharmacy [29][32] Influenza Vaccines - Influenza vaccine approvals totaled 29 batches, a significant increase of 263% year-on-year [34][38] - The three-valent influenza vaccine had 28 approvals, while the four-valent vaccine had only 1 approval, down 67% [38][41] Rabies Vaccines - Batch approvals for rabies vaccines increased to 223 in Q1 2025, a growth of 37% [46][48] - The freeze-dried rabies vaccine accounted for the majority of approvals, with Chengda Biological achieving 105 approvals, a 110% increase [48][46] Varicella Vaccines - Varicella vaccine approvals slightly decreased to 83 batches, down 2% [53][54] - The largest contributor was Baike Biological, with 33 approvals, marking a 38% increase [54][53] Hib Vaccines - Hib vaccine approvals fell to 7 batches, a decrease of 50% [59][58] EV71 Vaccines - EV71 vaccine approvals continued to decline, with only 4 batches approved, down 69% [64][63] Rotavirus Vaccines - Rotavirus vaccine approvals totaled 21 batches, a decrease of 46% [68][67] DTP Vaccines - DTP vaccine approvals increased to 18 batches, a growth of 167% [72][73] Meningitis Vaccines - Meningitis vaccine approvals totaled 85 batches, down 34% [78][79] - The AC polysaccharide vaccine accounted for 55 approvals, a decrease of 47% [84][79] Hepatitis B Vaccines - Hepatitis B vaccine approvals increased to 87 batches, a growth of 28% [91][90] IPV Vaccines - IPV vaccine approvals totaled 22 batches, a decrease of 33% [93][92]

北京中伦（成都）律师事务所 关于成都康华生物制品股份有限公司 2024 年年度股东大会的 法律意见书 致：成都康华生物制品股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》等法律、法规及规范性文件的规定，北京中伦（成都）律师事务 所（以下简称"中伦"或"本所"）指派律师出席了成都康华生物制品股份有限 公司（以下简称"公司"）2024 年年度股东大会（以下简称"本次股东大会"）， 对本次股东大会的合法性进行见证并出具法律意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具日 以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信 用原则，进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完 - 1 - 法律意见书 整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗 漏，并承 ...

证券代码：300841 证券简称：康华生物 公告编号：2025-028 成都康华生物制品股份有限公司 （问题征集专题页面二维码） 特此公告。 成都康华生物制品股份有限公司 董事会 本公司及董事会全体成员保证信息披露内容的真实、准确、完整、没有虚 假记载、误导性陈述或重大遗漏。 成都康华生物制品股份有限公司（以下简称"公司"）《2024年年度报告》 及其摘要已于2025年4月19日在中国证券监督管理委员会指定的创业板信息披露 网站巨潮资讯网（http://www.cninfo.com.cn）上披露。为使投资者进一步了解公司 2024年年度经营情况，公司定于2025年5月14日（星期三）下午15:30-17:00在全景 网举办2024年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行， 投资者可登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次年度业 绩说明会。 2025 年 5 月 9 日 出席本次说明会的人员有：公司董事长王振滔先生，董事、总裁吴红波先生， 董事、副总裁兼财务负责人、董事会秘书吴文年先生，独立董事方小波先生（如 有特殊情况，参与人员可能进行调整）。 为充分尊 ...

证券代码：300841 证券简称：康华生物 公告编号：2025-027 成都康华生物制品股份有限公司 2024年年度股东大会决议公告 特别提示： 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有出现否决议案的情况； 2、本次股东大会不涉及变更以往股东大会已通过决议的情况。 一、会议召开和出席的情况 6、本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》等的规定。 （二）会议出席情况 （一）会议召开情况 1、会议召开时间： （1）现场会议召开时间：2025年5月9日（星期五）下午14:30。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025年5月9日上午9:15-9:25，9:30-11:30，下午13:00-15:00；通过深圳证券 交易所互联网投票系统投票的具体时间为：2025年5月9日上午9:15—下午15:00期 间的任意时间。 2、会议召开方式：本次股东大会采取现场投票与网络投票相结合的方式。 3、会议召开地点：四川省成都市龙泉驿区北京路182号会议室。 4 ...

证券研究报告 2025 年 04 月 29 日 湘财证券研究所 公司研究 康华生物（300841.SZ）业绩点评 狂苗销量阶段性下降，渠道拓展稳步推进 相关研究： 1. 《狂苗领域技术及临床先发 优势明显，诺如疫苗带来业绩新 增长极》 20241203 公司评级：买入（维持） 近十二个月公司表现 % 1 个月 3 个月 12 个月 相对收益 11 -7 -18 绝对收益 13 1 -29 核心要点： ❑ 公允价值变动影响 2024Q4 利润端，高基数及费用率上升影响 2025Q1 业绩 根据公司 2024 年年报及 2025 年一季报，2024Q4 公司实现营业收入 3.71 亿元，受参股公司确认公允价值变动损失影响（合计-5868.82 万元），归母 净利润为-725 万元，扣非归母净利润 4492.55 万元。2024Q1 公司营收 3.11 亿元，其中包括重组六价诺如病毒疫苗海外授权首付款 1.06 亿元，剔除上 年同期首付款后，2025Q1 营收同比下降 32.75%，扣非归母净利润同比下 降 65.5%。 2024 年受研发项目阶段性投入减少，研发费用率为 9.22%，同比下降 6.82pct；受市 ...

Core Viewpoint - 康华生物 has demonstrated stable performance in 2024, driven by its core product, the lyophilized human rabies vaccine (human diploid cells), achieving a revenue of 1.432 billion yuan and a net profit of 399 million yuan [1][2] Financial Performance - In 2024, 康华生物 reported a revenue of 1.432 billion yuan, a net profit attributable to shareholders of 399 million yuan, and a net cash flow from operating activities of 572 million yuan [1][2] - For Q1 2025, the company achieved a revenue of 138 million yuan and a net profit of approximately 20.71 million yuan, showing a significant decline year-on-year primarily due to a high base from last year's overseas licensing income [2][3] - The bioproducts segment maintained a high gross margin of 93.74%, reflecting a year-on-year increase of 0.26% [1][3] Product Development and Pipeline - The core product, the lyophilized human rabies vaccine, had a batch release volume of 3.8976 million doses, with production expansion projects nearing completion and awaiting production license approval [2][3] - 康华生物 has seven projects in its research pipeline, including the hexavalent norovirus vaccine and the ACYW135 meningococcal polysaccharide vaccine, with three expected to enter clinical trials between 2025 and 2026 [4][5] Market Position and Competitive Advantage - 康华生物 is recognized for its advanced research and product capabilities in the rabies vaccine sector, maintaining a significant competitive edge due to its early entry into the market with the human diploid cell rabies vaccine [5][6] - The human diploid cell vaccine is considered the "gold standard" for rabies immunization, offering higher safety and immunogenicity compared to traditional Vero cell vaccines [6][7] - The market for human rabies vaccines remains substantial, with increasing public awareness and demand for rabies prevention measures due to rising pet and stray animal populations [7]

Core Viewpoint - Kanghua Biotech reported stable performance amidst industry challenges, with a focus on innovation and market expansion, particularly through the commercialization of its six-valent norovirus vaccine [1][2][3] Financial Performance - In 2024, Kanghua Biotech achieved revenue of 1.432 billion yuan and a net profit of 457 million yuan [1] - Despite a general decline in the vaccine sector, Kanghua's performance remained stable, with many competitors experiencing significant revenue and profit drops [1] Product Development and Market Strategy - The six-valent norovirus vaccine has been licensed out to HilleVax for development and commercialization outside China, marking a significant milestone with a total deal value of up to $2.555 billion [2] - The norovirus vaccine addresses a critical global health issue, with an estimated 700 million infections and 200,000 deaths annually, and is projected to enter the market by 2026 [3] - Kanghua is also advancing other vaccine candidates, including ACYW135 meningococcal conjugate vaccine and human rabies vaccine, with clinical trials planned for 2025 [3] Industry Trends and Growth Potential - The vaccine industry is characterized by high barriers to entry, requiring long-term investment in R&D and market development [4] - There is significant growth potential in the domestic vaccine market, with estimates suggesting a 2-8 times growth compared to developed countries [5] - Kanghua's strategy includes expanding into international markets and developing multiple innovative vaccine platforms, positioning the company for future growth [5] Investor Sentiment and Corporate Actions - Recent reports indicate increased investment from patient capital, with notable shareholders increasing their stakes in Kanghua [6] - The company announced a share buyback plan, converting 3 million shares for cancellation, which is seen as a positive signal of confidence in its long-term value [6]

Core Viewpoint - Chengdu Kanghua Biological Products Co., Ltd. has reported a decline in both revenue and net profit for 2024 and the first quarter of this year, with a significant drop of over 80% in net profit for Q1. This marks the second consecutive year of declining profits, with a substantial decrease in the batch release quantity of its core product, the freeze-dried human rabies vaccine (human diploid cells) [1][3][4]. Financial Performance - In 2024, the company achieved revenue of 1.432 billion yuan, a year-on-year decrease of 9.23%, and a net profit of 399 million yuan, down 21.71% [3]. - For Q1 2025, revenue was 138 million yuan, reflecting a 55.70% year-on-year decline. The net profit for the same period was 20.71 million yuan, a decrease of 86.15% [4]. Product Performance - The batch release quantity of the freeze-dried human rabies vaccine was 3.8976 million doses in 2024, a decrease of 43.83% compared to the previous year. This decline is attributed to improved inventory management and adjustments in production and batch release plans [3]. - The company has only two marketable products, with the freeze-dried human rabies vaccine accounting for over 97% of its revenue [5]. Market Competition - The market for human rabies vaccines is becoming increasingly competitive, with new entrants such as Shenzhen Kangtai Biological Products Co., Ltd. launching their own human diploid cell rabies vaccine, which has already surpassed Kanghua's batch release quantity in its first year [7][8]. - Other competitors like Zhifei Biological and Chengda Biological have also submitted applications for their own human rabies vaccines, which could further intensify competition in the market [8]. Strategic Developments - In January 2024, the company signed an exclusive licensing agreement with HilleVax for the development and commercialization of a six-valent norovirus vaccine outside of China, with potential milestone payments and royalties involved. However, this is not expected to have a significant short-term impact on financial performance [3].